Dr. Sandeep Gupta is the Chief Executive Officer of Leukogene Therapeutics, a biopharmaceutical company focused on developing innovative cancer immunotherapies, with particular emphasis on immunologically “cold” tumors.

Dr. Gupta has over 25 years of leadership experience across the pharmaceutical and biotechnology industries, spanning drug discovery, clinical development, corporate strategy and fundraising. Prior to Leukogene, he founded Asana BioSciences, where he served as CEO and President. Under his leadership, seven INDs were filed, advancing multiple pipeline assets from discovery through Phase 1–3 clinical development in oncology and immunology/inflammatory diseases. During this period, Dr. Gupta successfully out-licensed several key assets, including the dual SYK/JAK inhibitor gusacitinib to Libertas Bio/Sanofi and the ERK inhibitor ASN007 to Erasca.

Previously, Dr. Gupta served as CEO of Kashiv BioSciences LLC, a biopharmaceutical company focused on the development and manufacturing of biosimilars, and earlier as CEO of Libertas Bio, a subsidiary of Formation Bio. His prior senior leadership roles include Senior Vice President of Discovery and Early Development at Endo Health Solutions and Head of Discovery and Pharmacology at Forest Laboratories.

Dr. Gupta has also held academic appointments at the University of Pennsylvania and Boston University Schools of Medicine. He is an inventor on more than 20 patents and has authored over 50 scientific publications and book chapters. He is a member of ASCO and AACR and previously served as a member of The CEO Roundtable on Cancer.